Silver Book Fact

Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.

Kurlan R, Clark S, Shoulson I, Penny J. Economic Impact of Protective Therapy for Early Parkinson’s Disease. Ann Neurol. 1988; 24(1): 153

Reference

Title
Economic Impact of Protective Therapy for Early Parkinson’s Disease
Publication
Ann Neurol
Publication Date
1988
Authors
Kurlan R, Clark S, Shoulson I, Penny J
Volume & Issue
Volume 24, Issue 1
Pages
153

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.